Stockscreener 앱 받기
323.02
1.31%
-4.29
시간 외 거래:
323.02
Madrigal Pharmaceuticals Inc 주식(MDGL)의 최신 뉴스
Madrigal Pharmaceuticals Announces Changes to Board of Directors - MyChesCo
Madrigal Pharmaceuticals’ SWOT analysis: Rezdiffra success drives stock potential - Investing.com India
Madrigal Pharmaceuticals SVP and CFO sells stock for $83,344 By Investing.com - Investing.com Australia
Madrigal Pharmaceuticals SVP and CFO sells stock for $83,344 - Investing.com
Victory Capital Management Inc. Has $21.80 Million Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - Defense World
Bank of New York Mellon Corp Lowers Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - Defense World
Madrigal Pharmaceuticals appoints new board member By Investing.com - Investing.com Australia
How the (MDGL) price action is used to our Advantage - Stock Traders Daily
Madrigal Pharmaceuticals Expands Board with New Appointment - TipRanks
Madrigal appoints Jacqualyn Fouse to its board -March 11, 2025 at 09:36 am EDT - Marketscreener.com
Madrigal Appoints Jacqualyn A. Fouse, Ph.D. To Board - citybiz
Madrigal Pharmaceuticals appoints new board member - Investing.com India
Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors - The Manila Times
Why Madrigal Pharmaceuticals (MDGL) Stock is Rising Today - GuruFocus.com
Robert E. Waltermire Sells 14,113 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stock - Defense World
Insider Sale at Madrigal Pharmaceuticals Inc (MDGL): Senior VP, - GuruFocus.com
Madrigal Pharmaceuticals Exec Cashes Out in Multi-Million Dollar Stock Sale! - TipRanks
Madrigal Pharmaceuticals’ senior VP sells $4.8 million in stock By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals’ senior VP sells $4.8 million in stock - Investing.com India
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stock Holdings Reduced by Principal Financial Group Inc. - Defense World
Madrigal Pharmaceuticals CFO Mardi sells $637,247 in stock - Investing.com India
Madrigal Pharmaceuticals exec sells $418,488 in stock By Investing.com - Investing.com South Africa
Madrigal Pharmaceuticals exec sells $418,488 in stock - Investing.com
Madrigal Pharmaceuticals (NASDAQ:MDGL) Trading Down 6.8% on Insider Selling - Defense World
B. Riley Analysts Increase Earnings Estimates for MDGL - Defense World
Sanctuary Advisors LLC Acquires 62 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - Defense World
HC Wainwright Issues Negative Estimate for MDGL Earnings - Defense World
Madrigal Pharmaceuticals Reports Strong 2024 Growth Fueled by Rezdiffra Launch - MSN
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives $351.67 Consensus PT from Analysts - MarketBeat
New York State Common Retirement Fund Sells 5,630 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Citigroup Boosts Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target to $469.00 - Defense World
Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Up After Better-Than-Expected Earnings - MarketBeat
Madrigal Pharmaceuticals director Kenneth Bate sells $7.1m in stock By Investing.com - Investing.com Australia
(MDGL) Trading Report - Stock Traders Daily
Madrigal Pharmaceuticals director Kenneth Bate sells $7.1m in stock - Investing.com
Citigroup Issues Positive Forecast for Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Price - MarketBeat
Madrigal Pharmaceuticals: Rezdiffra First-Mover Advantage Gains Traction (Upgrade) (MDGL) - Seeking Alpha
Madrigal Pharmaceuticals price target raised to $239 from $154 at BofA - Yahoo Finance
Madrigal Pharmaceuticals (NASDAQ:MDGL) Given New $405.00 Price Target at HC Wainwright - MarketBeat
B. Riley Upgrades Madrigal Pharmaceuticals to Buy From Neutral, Raises Price Target to $422 From $236 - Marketscreener.com
Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Up After Strong Earnings - Defense World
Madrigal’s Earnings Call Highlights Strong Growth - TipRanks
Madrigal Pharmaceuticals price target raised to $443 from $427 at Citizens JMP - TipRanks
Decoding Madrigal Pharmaceuticals's Options Activity: What's the Big Picture? - Benzinga India
Madrigal Pharmaceuticals (NASDAQ:MDGL) Releases Quarterly Earnings Results, Beats Estimates By $1.61 EPS - MarketBeat
Madrigal Pharmaceuticals Shares Still Undervalued Amid Long-Term Growth Potential, UBS Says - Marketscreener.com
UBS maintains Buy on Madrigal Pharmaceuticals, target at $441 - Investing.com India
UBS maintains Buy on Madrigal Pharmaceuticals, target at $441 By Investing.com - Investing.com UK
Madrigal Pharmaceuticals upgraded to Buy from Neutral at B. Riley - TipRanks
Madrigal Pharmaceuticals Inc (MDGL) Q4 2024 Earnings Call Highli - GuruFocus.com
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q4 2024 Earnings Call Transcript - Insider Monkey
Madrigal Pharmaceuticals price target raised to $469 from $378 at Citi - TipRanks
We're Not Worried About Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn - Yahoo Finance
High Growth Tech Stocks In US For February 2025 - Yahoo Finance
Madrigal Pharmaceuticals Reports Promising Two-Year Results for MASH Therapy - MSN
1.39%
0.55%
자본화:
|
볼륨(24시간):